The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review.
Journal
Applied health economics and health policy
ISSN: 1179-1896
Titre abrégé: Appl Health Econ Health Policy
Pays: New Zealand
ID NLM: 101150314
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
21
10
2020
pubmed:
29
12
2020
medline:
23
11
2021
entrez:
28
12
2020
Statut:
ppublish
Résumé
Cancer poses a substantial health and economic burden on patients and caregivers in Canada. Previous reviews have estimated the indirect cost burden as work-related productivity losses associated with cancer. However, these estimates require updating and complementing with more comprehensive data that include relevant dimensions beyond labor market costs, such as patient time, lost leisure time and home productivity losses. A systematic review of the literature was conducted to identify studies published from 2006 to 2020 that measured and reported the indirect costs borne by cancer patients and their caregivers in Canada, from the patient, caregiver, employer, and societal perspectives. Study characteristics and cost estimation methods were extracted from relevant studies. Costs estimates were reported and converted to 2020 CAD for the following categories: lost earnings, caregiving time costs, home production losses, patient time (leisure), morbidity-, disability-, premature mortality-related costs, friction costs, and overall productivity losses. A quality assessment of individual studies was conducted for included studies using the Newcastle-Ottawa Assessment Tool. In total, 3980 studies were identified, of which 18 Canadian studies met the inclusion criteria for review. One-third of the studies used or developed prediction models, 38% enrolled patient cohorts, and 27% used administrative databases. Over one-third of the studies were conducted at a national level (38%). All studies employed the human capital approach to estimate costs, and 16% also used the friction cost approach. Lost earnings were higher among self-employed patients (43% vs 24% among employees) and females ($8200 vs $3200 for males). Caregiver costs ranged from $15,786 to $20,414 per patient per year. Household productivity losses were estimated to be up to $238,904 per household per year. Patient time (leisure) costs were estimated to be between $13,000 and $18,704 per patient per year. Premature annual mortality costs were estimated to be $2.98 billion overall in Quebec. Friction costs incurred by employers were estimated between $6400 and $23,987 per patient per year. Societal productivity losses associated with cancer were estimated between $75 million to $317 million, annually. This review suggests that the indirect cost burden of cancer is considerable from the patient, caregiver, employer, and societal perspectives. This up-to-date review of the literature provides a comprehensive understanding of the indirect cost burden by including non-labor market activity costs and by examining all relevant perspectives. These results provide a strong case for the government and employers to ensure there are supports in place to help patients and caregivers buffer the impact of cancer so they can continue to engage in productive activities and enjoy leisure time.
Sections du résumé
BACKGROUND AND OBJECTIVES
Cancer poses a substantial health and economic burden on patients and caregivers in Canada. Previous reviews have estimated the indirect cost burden as work-related productivity losses associated with cancer. However, these estimates require updating and complementing with more comprehensive data that include relevant dimensions beyond labor market costs, such as patient time, lost leisure time and home productivity losses.
METHODS
A systematic review of the literature was conducted to identify studies published from 2006 to 2020 that measured and reported the indirect costs borne by cancer patients and their caregivers in Canada, from the patient, caregiver, employer, and societal perspectives. Study characteristics and cost estimation methods were extracted from relevant studies. Costs estimates were reported and converted to 2020 CAD for the following categories: lost earnings, caregiving time costs, home production losses, patient time (leisure), morbidity-, disability-, premature mortality-related costs, friction costs, and overall productivity losses. A quality assessment of individual studies was conducted for included studies using the Newcastle-Ottawa Assessment Tool.
RESULTS
In total, 3980 studies were identified, of which 18 Canadian studies met the inclusion criteria for review. One-third of the studies used or developed prediction models, 38% enrolled patient cohorts, and 27% used administrative databases. Over one-third of the studies were conducted at a national level (38%). All studies employed the human capital approach to estimate costs, and 16% also used the friction cost approach. Lost earnings were higher among self-employed patients (43% vs 24% among employees) and females ($8200 vs $3200 for males). Caregiver costs ranged from $15,786 to $20,414 per patient per year. Household productivity losses were estimated to be up to $238,904 per household per year. Patient time (leisure) costs were estimated to be between $13,000 and $18,704 per patient per year. Premature annual mortality costs were estimated to be $2.98 billion overall in Quebec. Friction costs incurred by employers were estimated between $6400 and $23,987 per patient per year. Societal productivity losses associated with cancer were estimated between $75 million to $317 million, annually.
CONCLUSIONS
This review suggests that the indirect cost burden of cancer is considerable from the patient, caregiver, employer, and societal perspectives. This up-to-date review of the literature provides a comprehensive understanding of the indirect cost burden by including non-labor market activity costs and by examining all relevant perspectives. These results provide a strong case for the government and employers to ensure there are supports in place to help patients and caregivers buffer the impact of cancer so they can continue to engage in productive activities and enjoy leisure time.
Identifiants
pubmed: 33368032
doi: 10.1007/s40258-020-00619-z
pii: 10.1007/s40258-020-00619-z
pmc: PMC8060233
doi:
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
325-341Références
Canadian Cancer Statistics 2019. Canadian Cancer Society: Government of Canada; 2019.
Table 13-10-0394-01: leading causes of death, total population, by age group. Statistics Canada: Government of Canada; 2019.
Brenner DR, Weir HK, Demers AA, Ellison LF, Louzado C, Shaw A, et al. . Projected estimates of cancer in Canada in 2020. CMAJ. 2020;192(9):E199–205.
doi: 10.1503/cmaj.191292
Pisu M, Azuero A, McNees P, Burkhardt J, Benz R, Meneses K. The out of pocket cost of breast cancer survivors: a review. J Cancer Surviv. 2010;4(3):202–9.
doi: 10.1007/s11764-010-0125-y
Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol. 2014;20(4):327–37.
doi: 10.3350/cmh.2014.20.4.327
de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, et al. . The economic burden of cancer care in Canada: a population-based cost study. CMAJ Open. 2018;6(1):E1–10.
doi: 10.9778/cmajo.20170144
Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomark Prev. 2011;20(10):2006–14.
doi: 10.1158/1055-9965.EPI-11-0650
Canada PHAo. Economic burden of illness in Canada 2005–2008. PHAC. 2014.
Hopkins RB, Goeree R, Longo CJ. Estimating the national wage loss from cancer in Canada. Curr Oncol. 2010;17(2):40–9.
doi: 10.3747/co.v17i2.477
Geiger AM, O'Mara AM, McCaskill-Stevens WJ, Adjei B, Tuovenin P, Castro KM. Evolution of cancer care delivery research in the NCI Community Oncology Research Program. J Natl Cancer Inst. 2019;112(6):557–61.
doi: 10.1093/jnci/djz234
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
doi: 10.1371/journal.pmed.1000097
Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. . The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Hospital of Ottawa. 2019.
Bank of Canada's Inflation Calculator: Bank of Canada; 2020. https://www.bankofcanada.ca/rates/related/inflation-calculator/ . Accessed 3 May 2020
Boucher P, Beauregard H. Le coût économique du cancer au Québec, en 2008. Coalition Priorite Cancer au Quebec; 2008.
de Oliveira C, Bremner KE, Ni A, Alibhai SM, Laporte A, Krahn MD. Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. J Cancer Surviv. 2014;8(1):9–20.
doi: 10.1007/s11764-013-0305-7
Dumont S, Jacobs P, Turcotte V, Turcotte S, Johnston G. Palliative care costs in Canada: a descriptive comparison of studies of urban and rural patients near end of life. Palliat Med. 2015;29(10):908–17.
doi: 10.1177/0269216315583620
Jeon SH. The long-term effects of cancer on employment and earnings. Health Econ. 2017;26(5):671–84.
doi: 10.1002/hec.3342
Jeon SH, Pohl RV. Health and work in the family: Evidence from spouses’ cancer diagnoses. J Health Econ. 2017;52:1–18.
doi: 10.1016/j.jhealeco.2016.12.008
Jung YL, Tompa E, Longo C, Kalcevich C, Kim J, Song C, et al. . The economic burden of bladder cancer due to occupational exposure. J Occup Environ Med. 2018;60(3):217–25.
doi: 10.1097/JOM.0000000000001242
Krueger H, Andres EN, Koot JM, Reilly BD. The economic burden of cancers attributable to tobacco smoking, excess weight, alcohol use, and physical inactivity in Canada. Curr Oncol. 2016;23(4):241–9.
doi: 10.3747/co.23.2952
Krueger H, Williams D, Chomiak M, Trenaman L. The economic burden of skin cancer in Canada: current and projected. Can Partnersh Against Cancer; 2010. http://krueger.ca/wp-content/uploads/2015/08/skincancer.pdf . Accessed 30 April.
Lauzier S, Maunsell E, Drolet M, Coyle D, Hebert-Croteau N. Validity of information obtained from a method for estimating cancer costs from the perspective of patients and caregivers. Qual Life Res. 2010;19(2):177–89.
doi: 10.1007/s11136-009-9575-y
Lauzier S, Maunsell E, Drolet M, Coyle D, Hebert-Croteau N, Brisson J, et al. . Wage losses in the year after breast cancer: extent and determinants among Canadian women. J Natl Cancer Inst. 2008;100(5):321–32.
doi: 10.1093/jnci/djn028
Longo CJ, Fitch M, Deber RB, Williams AP. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer. 2006;14(11):1077–85.
doi: 10.1007/s00520-006-0088-8
Mofidi A, Tompa E, Spencer J, Kalcevich C, Peters CE, Kim J, et al. . The economic burden of occupational non-melanoma skin cancer due to solar radiation. J Occup Environ Hyg. 2018;15(6):481–91.
doi: 10.1080/15459624.2018.1447118
Smetanin P, Stiff D, Briante C, Ahmad S, Wong L, Ler A. Life and economic burden of lung disease in Ontario: 2011 to 2041. Risk Analytica, on behalf of the Ontario Lung Association; 2011.
Tompa E, Kalcevich C, McLeod C, Lebeau M, Song C, McLeod K, et al. . The economic burden of lung cancer and mesothelioma due to occupational and para-occupational asbestos exposure. Occup Environ Med. 2017;74(11):816–22.
doi: 10.1136/oemed-2016-104173
Tsimicalis A, Stevens B, Ungar WJ, Greenberg M, McKeever P, Agha M, et al. . Determining the costs of families’ support networks following a child’s cancer diagnosis. Cancer Nurs. 2013;36(2):E8–19.
doi: 10.1097/NCC.0b013e3182551562
Tsimicalis A, Stevens B, Ungar WJ, McKeever P, Greenberg M, Agha M, et al. . A prospective study to determine the costs incurred by families of children newly diagnosed with cancer in Ontario. Psychooncology. 2012;21(10):1113–23.
doi: 10.1002/pon.2009
Wranik WD, Muir A, Hu M. Costs of productivity loss due to occupational cancer in Canada: estimation using claims data from Workers’ Compensation Boards. Health Econ Rev. 2017;7(1):9.
doi: 10.1186/s13561-017-0145-7
Yu M, Guerriere DN, Coyte PC. Societal costs of home and hospital end-of-life care for palliative care patients in Ontario, Canada. Health Soc Care Commun. 2015;23(6):605–18.
doi: 10.1111/hsc.12170
Brouwer WB, Koopmanschap MA. The friction-cost method : replacement for nothing and leisure for free? Pharmacoeconomics. 2005;23(2):105–11.
doi: 10.2165/00019053-200523020-00002
Pike J, Grosse SD. Friction cost estimates of productivity costs in cost-of-illness studies in comparison with human capital estimates: a review. Appl Health Econ Health Policy. 2018;16(6):765–78.
doi: 10.1007/s40258-018-0416-4
CADTH. Guidelines for the economic evaluation of health technologies: Canada. 4th edition; Ottawa; 2017.